Not Signed In - Roche And Kosan To Initiate Phase 2 Cancer Development Program With Epothilone R1645 (KOS-1584)
Wed, 28 Feb 2007 08:00 AM EST
... Roche and Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that the companies have selected their second-generation epothilone R1645 (KOS- 1584) to advance into a Phase 2 clinical development program exploring clinical activity and safety in multiple solid tumor types. [click link for full article] ...
Related Topics
- Child Development
- Community Development
- Fetal Development
- Teen Development
- Clinical Trials
- Cancers
- Prostate Cancer
- Development of a second primary colorectal cancer
- Cervical Cancer
- Brain Cancer
- Kidney Cancer
- Pancreatic Cancer
- Testicular Cancer
- Esophageal Cancer
- Colon Cancer
- Uterine Cancer
- Infant and Toddler Development
- Liver Cancer
- Thyroid Cancer
- Breast Cancer
email this page
print this page
bookmark this page
feedback on this page